Atea Pharmaceuticals logo
Atea Pharmaceuticals
AVIR | NASDAQ
Chart Builder DCF Calculator
$4.12
-$0.18 (-4.19%)
At close: Nov 16, 2026, 4:00 PM ET
$4.12
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Atea Pharmaceuticals Company Profile

Company profile explained

Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Key Executives

Name Position
Jean-Pierre Sommadossi Founder, Chairman, Chief Executive Officer & President
Andrea J. Corcoran Chief Financial Officer, Executive Vice President of Legal & Secretary
Adel Moussa Executive Vice President of Chemistry
Janet J. Hammond Chief Development Officer
John F. Vavricka Chief Commercial Officer
Jonae R. Barnes Senior Vice President of Investor Relations & Corporate Communications
Keith Pietropaolo Executive Vice President of Clinical Sciences & Project Management
Maria Arantxa Horga Chief Medical Officer
Wayne Foster Executive Vice President of Finance & Chief Accounting Officer
Xiao-Jian Zhou Executive Vice President of Early Stage Development

Latest SEC Filings

Date Type Title
Oct 06, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 12, 2026 10-Q Quarterly Report
Aug 12, 2026 8-K Current Report
Jun 23, 2026 4 Filing
Jun 23, 2026 4 Filing
Jun 23, 2026 4 Filing
Jun 23, 2026 4 Filing
Jun 23, 2026 4 Filing
Jun 23, 2026 4 Filing
Jun 23, 2026 4 Filing
View All SEC Filings ➞
Atea Pharmaceuticals
Atea Pharmaceuticals logo
Country United States
IPO Date Oct 30, 2020
Industry Biotechnology
Sector Healthcare
Employees 55
CEO Jean-Pierre Sommadossi

Contact Details

225 Franklin Street Boston, Massachusetts 02110 United States

Stock Details

Ticker Symbol AVIR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001593899
CUSIP Number 04683R106
ISIN Number US04683R1068
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.